Lithuania operates a preventive screening program designed for the early detection of prostate cancer. This initiative targets men within a specific age bracket: those between 50 and 69 years old, inclusive. An earlier screening threshold is available for men aged 45 if there is a documented family history of prostate cancer among their parents or brothers.
Participation in the screening involves periodic testing to measure the concentration of prostate-specific antigen (PSA) in the blood. If the PSA level registers above established normal parameters, the process mandates a referral. The family doctor will issue this referral, directing the individual to consult with a urologist.
The urologist may subsequently recommend a prostate biopsy if clinical evaluation deems it necessary. Crucially, the guidelines emphasize that a diagnosis of prostate cancer does not automatically necessitate active treatment. Medical professionals stress that not all instances of prostate cancer carry equal risk.
Expert commentary highlights that risk stratification is a key component of patient management. For instance, low-risk findings, defined by parameters such as a PSA level below 10, a Gleason score of 6 or less, and a clinical T-stage of T1, suggest a different management approach than more advanced cases. This multi-step screening and diagnostic pathway ensures that men are assessed according to established medical protocols, balancing the need for early detection with the necessity of avoiding unnecessary intervention.
Topics: #prostate #cancer #program
